Growing sector – growing guide
Thicker than ever: The 21st edition of the Guide to German Biotech Companies has been published. Almost 120 companies from the vibrant biotech sector present themselves in the English-language yearbook.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2175 entries already.
Entries by Thomas Gabrielczyk
Novo secures Dicerna’s RNAi liver assets
Danish Novo Nordisk A/S has secured access to Dicerna Inc’s GalXC RNAi technology in a R&D deal worth US$225m upfront over three years comprising 30 liver targets.
EU with poor success in fighting superbugs
The EU has made poor progress combatting antimicrobial resistance, a report from the European Court of Auditors (ECA) warns. Innovators need to be supported, urges the BEAM Alliance.
Cellectis presents way to safer CAR-Ts
Researchers at French-US allogeneic CAR-T cell developer Cellectis SA have designed an engineered CAR-T cell that secretes IL-12 upon contact with tumour cells.
Magenta Therapeutics exercises ATAC licence option
Magenta Therapeutics has exercised the option to licence Heidelberg Pharma AG’s anti-CD45-Antibody Targeted Amanitin Conjugate (ATAC).
Increase Your Culture Yields with Fibra-Cel Disks
Fibra-Cel® Disks are an advanced, solid support material for the efficient growth of mammalian and insect cells in bioreactors. They are devised to improve the cultivation of anchorage-dependent as well as suspension cells. Fibra-Cel Disks can be used also for perfusion cell culture with the Eppendorf packed-bed impeller – available for glass, stainless steel, and single-use bioreactors.
SciRhom targets autoimmunity switch
Autoimmunity specialist SciRhom GmbH has kicked of a first-in-class antibody development programme targeting iRhom2.
CPhI: The Pharma Awards winners
At the CPhI Worldwide in Frankfurt, the winners of the 2019 Pharma awards were announced. The CEO of WuXi AppTec, Dr. Ge Li, received the award in category CEO of the year among 12 other categories.
AMR: ENABLE selects Mutabilis candidate
A drug combo breaking antibiotic resistance of Gram-negative priority pathogens has been selected under the ENABLE programme of the Innovative Medicines Initiative (IMI).
NSCLC: Bemcentinib + anti-PD1 triple PFS
Bergen Bio ASA’s Axl kinase blocker bemcentinib in combination with MSD’s pembrolizumab has met the primary endpoint in a Phase II study in patients with non small cell lung cancer (NSCLC).